Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11238723 | 0.97 | CHRNA7 (0.43) | CHRNA7BCHEACHELMNATHRB | |
| SCHEMBL13146092 | 0.82 | — | — | |
| SCHEMBL4906320 | 0.77 | CHRNA7 (0.41) | CHRNA7BCHEACHELMNACHKA | |
| SCHEMBL4893867 | 0.73 | APOBEC3A (0.39) | CHRNA7 | |
| SCHEMBL4903990 | 0.69 | CHRNA7 (0.38) | CHRNA7BCHEACHECHKA | |
| SCHEMBL1666073 | 0.67 | CHRNA7 (0.36) | CHRNA7BCHEACHECHKA | |
| SCHEMBL12036494 | 0.67 | CHRNA7 (0.36) | CHRNA7BCHEACHECHKA | |
| SCHEMBL4896775 | 0.66 | KDM4E (0.40) | CHRNA7CHKA | |
| Water SCHEMBL8053367 | 0.65 | CHRNA7 (0.35) | CHRNA7BCHEACHECHKA | |
| SCHEMBL15434687 | 0.65 | CHRNA7 (0.35) | CHRNA7BCHEACHECHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | claimed |
| WO-2023250323-A1 | GPR119 AND GPR40 AGONIST COMBINATION THERAPIES FOR GUT-BRAIN AXIS DISORDERS | KALLYOPE, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3357926-A1 | TRANSDERMAL DELIVERY SYSTEMS OF BETA-LACTAM ANTIBIOTICS | Yu, Chongxi (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-1867667-B1 | Method for manufacturing stabilized polyacetal resin | POLYPLASTICS CO (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-8183273-B2 | 8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disease | TOBIRA THERAPEUTICS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20080271381-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | POLYPLASTICS CO., LTD (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080249147-A1 | Emulsion-Stabilized Preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080234343-A1 | Preparation with Elevated Content | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7410958-B2 | Triterpene quaternary salts as biologically active surfactants | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7371772-B2 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20080031942-A1 | Solid Preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1867667-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | Polyplastics Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20070088009-A1 | TRITERPENE QUATERNARY SALTS AS BIOLOGICALLY ACTIVE SURFACTANTS | KRASUTSKY PAVEL A | 2007-04-19 | — | — | US | disclosed |
| US-7199114-B2 | Triterpene quaternary salts as biologically active surfactants | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249147-A1 | Emulsion-Stabilized Preparation | LIPA, MGLL, SI | CHRNA7 3798/4885BCHE 3404/4885ACHE 2866/4885 |
| US-20080234343-A1 | Preparation with Elevated Content | SI, CEL, ABCB11 | CHRNA7 3235/4885BCHE 433/4885ACHE 259/4885 |
| US-20070088009-A1 | TRITERPENE QUATERNARY SALTS AS BIOLOGICALLY ACTIVE SURFACTANTS | BET1, PGGT1B, RABGGTB | CHRNA7 2494/4885BCHE 545/4885ACHE 2340/4885 |
| US-20080031942-A1 | Solid Preparation | PGA5, ABCG2, ACMSD | CHRNA7 3816/4885BCHE 3802/4885ACHE 3260/4885 |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | CHRNA7 232/4885BCHE 1435/4885ACHE 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.